During pregnancy, a bidirectional transfer of molecules and cells takes place through the placenta, which can be considered a transfusion. For decades, we have wondered whether said transfusion can lead to a true TA-GVHD. We propose several factors that may influence production of TA-GVHD during pregnancy. In order to achieve this, we shall take into account possible destinations for transfused leukocytes, which represent extremely different scenarios and may include transfusion associated-graft versus host disease (TA-GVHD).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.transci.2022.103409 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Risk of introducing Zika virus in the Canadian cord blood supply: A risk analysis.
Transfusion
December 2024
Medical Affairs and Innovation, Héma-Québec, Montreal, Quebec, Canada.
Background: In Canada, as many as 24% of mothers are deferred from cord blood (CB) donation due to risk factors for Zika virus (ZIKV). However, the ZIKV epidemic has waned considerably since 2016, and there has not been any report of ZIKV transmission by CB transplantation, which questions this policy. Thus, we performed an analysis of the risk of introducing ZIKV in the CB supply maintained by Héma-Québec (HQ) and Canadian Blood Services (CBS).
View Article and Find Full Text PDFMetabolic alterations unravel the maternofetal immune responses with disease severity in pregnant women infected with SARS-CoV-2.
J Med Virol
December 2023
Department of Molecular and Cellular Medicine, Laboratory of Molecular Immunology, Institute of Liver and Biliary Sciences, New Delhi, India.
Pregnancy being an immune compromised state, coronavirus disease of 2019 (COVID-19) disease poses high risk of premature delivery and threat to fetus. Plasma metabolome regulates immune cellular responses, therefore we aimed to analyze the change in plasma secretome, metabolome, and immune cells with disease severity in COVID-19 positive pregnant females and their cord blood. COVID-19 reverse transcriptase-polymerase chain reaction positive pregnant females (n = 112) with asymptomatic (Asy) (n = 82), mild (n = 21), or moderate (n = 9) disease, healthy pregnant (n = 18), COVID-19 positive nonpregnant females (n = 7) were included.
View Article and Find Full Text PDFA safe and effective use of caplacizumab in pregnancy-related acquired thrombotic thrombocytopenic purpura.
Br J Haematol
August 2023
Division of Hematology/Oncology, Department of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Article Synopsis
- Thrombotic thrombocytopenic purpura (TTP) can occur during pregnancy, either as a first episode or an exacerbation of existing conditions, complicating treatment options.
- Use of caplacizumab, a medication approved for TTP treatment, is limited due to scarce data on its safety and effectiveness in pregnant patients, raising concerns about potential hemorrhage.
- Despite these concerns, a case study showed successful off-label use of caplacizumab in a pregnant patient with refractory TTP, leading to hematologic recovery and the delivery of a healthy baby, contributing valuable information to the limited literature on this treatment in pregnancy.
Premature birth associated with a favorable course in gestational alloimmune liver disease (GALD): A case report.
Front Pediatr
March 2023
Department of Pediatrics, University of Erlangen-Nürnberg, Erlangen, Germany.
Gestational alloimmune liver disease (GALD) is a rare neonatal disorder with high mortality and morbidity. The patients come to caregivers' attention aged a few hours or days. The disease manifests as acute liver failure with or without siderosis.
View Article and Find Full Text PDFCan maternofetal transfusion provoke adverse outcomes akin to TA-GVHD?
Transfus Apher Sci
April 2022
Colegio Nacional de Buenos Aires, Universidad de Buenos Aires, Bolivar 263, Buenos Aires, Argentina. Electronic address:
During pregnancy, a bidirectional transfer of molecules and cells takes place through the placenta, which can be considered a transfusion. For decades, we have wondered whether said transfusion can lead to a true TA-GVHD. We propose several factors that may influence production of TA-GVHD during pregnancy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!